Biotechnology Company in Nassau County, NY

Endocrine Technology LLC is a New York-based biotechnology company specializing in the development of innovative technologies and life-saving therapeutics. Our patented platform, ETBOND Technology, is approved in the USA and India and is transforming the landscape of global healthcare.

At Endocrine Technology LLC, we focus on improving patient outcomes by leveraging cutting-edge advancements in genomics and immunology, creating life-saving medicines that are more accessible and cost-effective.

Key Highlights of ETBOND Technology

1. Catalyst for the “Right to Try Law”
   ETBOND Technology is instrumental in supporting the Right to Try Law, introduced in most U.S. states, enabling millions of Americans to access life-saving medicines in a cost-effective manner. We believe that implementing similar laws globally will increase access to life-saving medicines worldwide.
2. Advancing Global Scientific Research
   Our technology builds on the work of over 20,450 global scientists, all of whom are listed in the PubMed Scientific Database. This collaboration advances critical research in genomics and immunology. PubMed Search Link
3. Recent Advances in Genomics & Immunology
   The work driven by ETBOND Technology details cutting-edge breakthroughs in genomics and immunology, leading to life-saving therapeutics that are a decade ahead of Nobel Prize-winning research and traditional scientific work from universities, consultants, and government institutions.
4. Redefining the Future of Healthcare
   By integrating our advances into existing and emerging treatments, ETBOND Technology is poised to redefine global healthcare and drive the future of medical therapeutics.

How We Achieve This: Leadership and Expertise

Kumar Shah, M.D., founder and consulting physician of ETBOND Technology, has over three decades of experience in life sciences and the biotechnology industry. He has worked closely with some of the world’s top experts, including Nobel Laureates:

• Dr. Roslyn Yalow, Nobel Laureate in Medicine (1977) for Radio Immunoassay Techniques.
• Dr. Barnett Zumoff and Dr. H. L. Trivedi, both of whom have made significant contributions to the medical field.

Dr. Shah also served as Clinical Research Director at the Hoffmann-La Roche Mumbai branch. His extensive background and dedication to advancing life-saving therapeutics have shaped the mission of Endocrine Technology LLC.

Innovative Drug Formulations and Therapeutics

1. Sodium Polystyrene Sulfonate Reformulation (Polysulfone Fibers)
   One of our most significant innovations is the reformulation of Sodium Polystyrene Sulfonate into Polysulfone fibers, which revolutionizes the treatment of hemodialysis. This new formulation reduces the risk of pulmonary complications and improves patient comfort during dialysis. The mechanism of action is consistent with recent advances in genomics and immunology, as it inhibits Factor H.
2. Globally Approved Generic Drug for Chronic Renal Failure
   The reformulated drug is an approved generic available globally to treat high potassium levels in patients with chronic renal failure. The drug works through its ion exchange properties, with a standard dosage of 120 grams per day, used by millions worldwide.
3. Improved Safety Data at ETBOND Clinic
   Through our ETBOND Clinic, we’ve generated significant safety data showing that our drug formulation reduces adverse effects and increases patient safety by over 100-fold, demonstrating the clinical impact of our innovations.

Impact Across Multiple Medical Fields

1. Cancer Care
   ETBOND’s technology serves as an advanced immune checkpoint inhibitor, allowing the body’s immune system to generate cytotoxic immune responses against cancer cells. This work builds on Nobel-winning advancements in T and B cell therapies.
2. Autoimmune Diseases
   We extend the advancements made in T and B cell reprogramming for autoimmune diseases, building on breakthroughs that won the 2025 Nobel Prize. Our work goes even further, focusing on diabetes and its associated vascular diseases.
3. Transplant Technology
   Our technology fills a critical gap in transplant medicine by preventing early organ rejection in heart, kidney, lung, and liver transplants. We also advance islet cell transplants, offering potential cures for Type 1 diabetes.
4. Orphan Diseases
   ETBOND’s innovations provide solutions for orphan diseases, especially those affecting the blood and kidneys. We are addressing atypical hemolytic disorders, blood transfusion incompatibility, and complement-mediated kidney diseases.
5. Pandemic Solutions (e.g., COVID-19)
   Our technology offers cutting-edge solutions to the challenges posed by pandemics like COVID-19, where the SARS-CoV-2 virus evades vaccines and antibodies. Our therapies offer a solution to prevent the recurrence of pandemics.
6. Cardiovascular Diseases
   Our drug also addresses acute myocardial infarction by inhibiting lipid disorders, inflammation, and coagulation disorders simultaneously. This provides prophylaxis and therapy for cardiovascular diseases. Learn More
7. Eye Diseases
   ETBOND’s technology also targets inflammatory eye diseases, which are a major cause of blindness. We provide advanced treatments for age-related macular degeneration and diabetic retinopathy.

Shaping the Future of Healthcare

At Endocrine Technology LLC, we are committed to revolutionizing the future of healthcare. By harnessing the power of genomics, immunology, and biotechnology, we aim to provide innovative solutions to the world’s most pressing medical problems, ensuring that life-saving treatments are available to all.